Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28,025 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Precision nephrotoxicity testing using 3D in vitro models.
Yu P, Zhu H, Bosholm CC, Beiner D, Duan Z, Shetty AK, Mou SS, Kramer PA, Barroso LF, Liu H, Cheng K, Ihnat M, Gorris MA, Aloi JA, Woldemichael JA, Bleyer A, Zhang Y. Yu P, et al. Among authors: zhu h. Cell Biosci. 2023 Dec 21;13(1):231. doi: 10.1186/s13578-023-01187-0. Cell Biosci. 2023. PMID: 38129901 Free PMC article. Review.
Beyond waste: understanding urine's potential in precision medicine.
Yu P, Bosholm CC, Zhu H, Duan Z, Atala A, Zhang Y. Yu P, et al. Among authors: zhu h. Trends Biotechnol. 2024 Feb 17:S0167-7799(24)00029-5. doi: 10.1016/j.tibtech.2024.01.009. Online ahead of print. Trends Biotechnol. 2024. PMID: 38369434 Free article. Review.
Noncanonical WNT5A controls the activation of latent TGF-β to drive fibroblast activation and tissue fibrosis.
Trinh-Minh T, Chen CW, Tran Manh C, Li YN, Zhu H, Zhou X, Chakraborty D, Zhang Y, Rauber S, Dees C, Lin NY, Kah D, Gerum R, Bergmann C, Kreuter A, Reuter C, Groeber-Becker F, Eckes B, Distler O, Fabry B, Ramming A, Schambony A, Schett G, Distler JH. Trinh-Minh T, et al. Among authors: zhu h. J Clin Invest. 2024 Mar 26;134(10):e159884. doi: 10.1172/JCI159884. J Clin Invest. 2024. PMID: 38747285
Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study.
Jin ZC, Chen JJ, Zhu XL, Duan XH, Xin YJ, Zhong BY, Chen JZ, Tie J, Zhu KS, Zhang L, Huang M, Piao MJ, Li X, Shi HB, Liu RB, Xu AB, Ji F, Wu JB, Shao GL, Li HL, Huang MS, Peng ZY, Ji JS, Yuan CW, Liu XF, Hu ZC, Yang WZ, Yin GW, Huang JH, Ge NJ, Qi X, Zhao Y, Zhou JW, Xu GH, Tu Q, Lin HL, Zhang YJ, Jiang H, Shao HB, Su YJ, Chen TS, Shi BQ, Zhou X, Zhao HT, Zhu HD, Ren ZG, Teng GJ; CHANCE2201 Investigators. Jin ZC, et al. Among authors: zhu hd. EClinicalMedicine. 2024 May 6;72:102622. doi: 10.1016/j.eclinm.2024.102622. eCollection 2024 Jun. EClinicalMedicine. 2024. PMID: 38745965 Free PMC article.
28,025 results
You have reached the last available page of results. Please see the User Guide for more information.